Rebutrix 150 mg. 500 mg FILM COATED TABLETS
PDF Leaflet Revision Date: 29 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced breast, colorectal, and gastric cancers.
Dosage (summary)
1,250 mg/mu00b2 twice daily for 14 days, followed by a 7-day rest period.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding during treatment and for 2 weeks after.
Key Drug Interactions
- Warfarin
- Phenytoin
- Leucovorin
- Sorivudine
Contraindications
- Hypersensitivity to capecitabine
- Severe renal impairment
- Severe hepatic impairment
- Dihydropyrimidine dehydrogenase deficiency
Common side effects
- Diarrhoea
- Nausea
- Fatigue
- Hand-foot syndrome
Counselling Points
- Take with water within 30 mins after meals.
- Report any severe diarrhoea or toxicity.
- Use effective contraception during treatment.
Serious warnings
- Monitor INR with anticoagulants
- Risk of severe mucocutaneous reactions
- Cardiotoxicity
Important Disclaimer
The Rebutrix 150 mg. 500 mg FILM COATED TABLETS professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
